2.Advances in Solid-state Fermentation of Microbial Lipase
Xiao-Feng WANG ; Yun-Jun YAN ;
China Biotechnology 2006;0(01):-
Lipases have catalytic active in both aqueous phase and the non-aqueous phase and have a wide range of application in various industrial areas.However,the high cost of lipase production has restricted its extensive use in industry.Solid state fermentation possesses many advantages,such as low requirement for devices,low energy consumption,low production cost,little pollution to environment and easily being popularized,which have made it an important means in microbial production of lipases.Owing to the rapidly increased energy cost and the people's awareness of environmental protection,the solid state fermentation technique,which was regarded as low-tech in the past,has regained attention and developed rapidly since the 1990s.The production of lipase by SSF technique was reviewed.Mainly contents describe its characteristics,including physical and chemical factors and bioreactors.
3.New principles in tumor antigens and their significance in future immunotherapies for lymphomas and other malignancies--editorial.
Xiao-Yan KE ; Jing WANG ; Xiao-Feng YANG
Journal of Experimental Hematology 2006;14(3):419-426
The molecular characterization of self-antigens expressed by human malignancies that are capable of elicitation of anti-tumor immune responses in patients has been an active field in hematology, oncology, and tumor immunology. More than 2000 tumor antigens have been identified. These significant progresses have led to the renaissance of tumor immunology and studies on novel anti-tumor immunotherapies in lymphomas, other hematologic malignancies and tumors. However, despite of the progress in the identification of these self-tumor antigens, current antigen-specific immunotherapies for tumors are far less satisfactory than that expected, which reflects the urgent need to improve our understanding on the basic principles underlying the selection of these self-tumor antigens. In order to develop more effective antigen-specific anti-tumor immunotherapies and to monitor the responses to these immunotherapies in patients with lymphomas and other malignancies, many additional questions need to be addressed. In this brief review, the progress in the identification of tumor antigens in lymphomas and other malignancies was outlined and the new principles of self-tumor antigens and their significance for future immunotherapies to these malignancies were summarized.
Antigens, Neoplasm
;
classification
;
immunology
;
therapeutic use
;
Autoantigens
;
classification
;
immunology
;
Hematologic Neoplasms
;
therapy
;
Humans
;
Immunotherapy
;
methods
;
trends
;
Lymphoma
;
immunology
;
therapy
;
Neoplasms
;
immunology
;
therapy
5.Advances in lymphangiogenesis and metastasis of tumor.
Xiao-chu YAN ; Dong-mei YU ; Feng-xuan LIU
Chinese Journal of Pathology 2005;34(6):370-372
Animals
;
Humans
;
Lymph Nodes
;
pathology
;
Lymphangiogenesis
;
physiology
;
Lymphatic Metastasis
;
Lymphatic Vessels
;
metabolism
;
pathology
;
Neoplasms
;
metabolism
;
pathology
;
Vascular Endothelial Growth Factor C
;
metabolism
;
physiology
;
Vascular Endothelial Growth Factor D
;
metabolism
;
physiology
6.One case of nasal septum chordoma.
Yan LIU ; Xin-yi LIU ; Xiao-feng ZHANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2012;47(6):514-515
Adult
;
Chordoma
;
Humans
;
Male
;
Nasal Septum
;
pathology
;
Nose Neoplasms
8.Pharmacokinetic study of iguratimod in rats
Feng XIAO ; Zhaoyi YANG ; Shangxue YAN ; Wei WEI
Chinese Journal of Primary Medicine and Pharmacy 2008;15(6):-
ObjectiveTo study the pharmacokinetics of iguratimod in rats. MethodsThe concentration ofiguratirnod in the samples was determined by HPLC method. The pharmacokineties parameters were calculated withDAS softwrare. ResultsThe mainpharmacokineties parameters of normal group(6mg/kg) were as follows:t1/2Ke:3.56h, tpeak: 4.00h, Cmax : 8.87μg/ml, AUC0.24 : 74.76μg· ml-1·h-1. The main pharmacokineties parameters of threemodel groups(3,6,12mg/kg) were as follows: t1/2Ke: 4.54,3.20,3.17h, tpcak:3.83,3.83,4.67h,Cmax:3.84, 8.31,12.69μg/ml, AUC0.24 :40.21,76. 72,117.06μg·ml-1·h-1. Except Cmax and AUC, no significant differenceswere found between the three model groups. And the differences between normal group and model group were notsignificant. ConclusionThe pharmacokinetics of rats ks fit to one-compartment model.
9.Expression of Survivin, Anti Apoptosis Gene in Leukemia and Correlation between Expression of Survivin,Fas and Caspase
yan-feng, XIAO ; ya, LIU ; wei, TIAN ; li-fen, REN
Journal of Applied Clinical Pediatrics 1986;0(01):-
Objective To explore the relation ship between expression of survivin gene in leukemia cells and its clinical effects, and to study the mechanism of survivin resist-apoptosis function in leukemia.Methods Survivin expression was detected by Western blots analysis and expressions of Fas and Caspase were examined by immunohistochemistry in 18 leukemia patients.Results Thirteen cases in peripheral blood mononuclear cell survivin positive expression was detected in 18 leukemia patients(72.2%), but no survivin expression in 10 normal persons. There were significant difference of survivin expression in ALL/ANLL patients groups and different WBC groups(P
10.Study on Refolding Ways of Recombinant pro-Carboxypeptidase B
Xiao-Yan ZHANG ; Hai-Feng LIU ; Qin-Sheng YUAN ;
Microbiology 1992;0(02):-
dialysis.